71例乳腺癌的病理特征分析  

作　　者：霍成[1] 张晖[1] 

机构地区：[1]大同市同煤集团总医院,山西037000

出　　处：《当代医学》2014年第8期17-18,共2页Contemporary Medicine

摘　　要：目的分析并总结71例乳腺癌患者的病理特征。方法回顾71例乳腺癌患者的临床资料。结果 71例乳腺癌患者中,浸润性导管癌最多见,约占85.92%(61/71),其次为导管内原位癌,约占11.27%(8/71);淋巴结转移43.66%(31/71)。71例患者中浸润性导管癌ER、PR的阳性表达率分别为52.50%(32/61)和49.18%(30/61),导管内原位癌ER、PR的阳性表达率均为50%(4/8);导管内原位癌与浸润性导管癌CerbB-2的阳性表达率分别为75%(6/8)和65.57%(40/61);导管内原位癌与浸润性导管癌的Ki-67阳性表达率分别为50%(4/8)和91.80%(56/61)。结论浸润性导管癌的组织学分级较差,侵袭性较强,淋巴结转移阳性率较高。对乳腺癌患者同时检测ER、PR、CerbB-2及Ki-67的表达水平,可以更好的指导乳腺癌患者的临床治疗。Objective To analyze and summarize the pathologic characteristics of 71 patients with breast cancer. Methods The clinical datas of 71 patients with breast cancer were analyzed retrospecively. Results In 71 cases with breast cancer, invasive ductal carcinoma was the most common type, accounts for about 85.92%（61/71）, followed by intraductal carcinoma in situ, accounts for about 11.27%（8/71）;Lymph node metastasis was 43.66%（31/71）. The ER and PR positive expression rate of invasive ductal carcinoma was 52.50%（32/61） and 49.18%（30/61）, the ER and PR positive expression rate of ductal carcinoma in situ was 50%（4/8）. The CerbB-2 positive expression rate of ductal carcinoma in situ and invasive ductal carcinoma was 75%（6/8） and 65.57%（40/61） respectively. The Ki-67 positive expression rate of ductal carcinoma in situ and invasive ductal carcinoma was 50%（4/8） and 91.80%（56/61） respectively. Conclusion The histologic classiifcation of invasive ductal carcinoma is relatively low, the invasive is stronger and the lymph node metastasis positive rate is higher. Detect the level of ER, PR,CerbB-2 and Ki-67 of the patients with breast cancer at the same time can better guide the clinical treatment of patients with breast cancer.

关 键 词：乳腺癌 病理 

分 类 号：R737.9[医药卫生—肿瘤]